Angiotensin Receptor Blockers (ARBs), Hydrochlorothiazide, Atenolol, Amlodipine Use and Celiac Disease

Project Title Angiotensin Receptor Blockers (ARBs), Hydrochlorothiazide, Atenolol, Amlodipine Use and Celiac Disease
Date Posted
Friday, June 7, 2013
Project ID
MSY3_MPR34
Status
Complete
Deliverables
Related Links
Description

Modular program-based one-time assessment of incident celiac disease events among new users of specific Angiotensin Receptor Blockers (ARBS) including olmesartan, candesartan, eprosartan, irbesartan, losartan, telmisartan, and valsartan and new users of hydrochlorothiazide, atenolol, and amlodipine.Two main categories of counts were generated: 1) incident counts with respect to each of the medications, and 2) incident Celiac Disease events for each exposure group per 1000 person-days at risk [January 2007 – December 2011]. Modular programs are adaptable standardized programs. Results were generated using Modular Program 3; click here for more information. Programs were executed in August 2012.

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.

The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

Medical Product
amlodipine
angiotensin II receptor blocker (ARB)
atenolol
candesartan
eprosartan
hydrochlorothiazide (HCTZ)
irbesartan
losartan
olmesartan
telmisartan
valsartan
Health Outcome
celiac disease
Time Period
2007 - 2011
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Mini-Sentinel Distributed Database (MSDD)
FDA Center
CDER